Gilead Oncology on Twitter
WEBJul 13, 2023 · “Understanding the complexities of who blood cancer affects and the way it behaves may help explain the variability of a person’s response to treatment. Teresa Sadras, a Gilead Research Scholars Program grantee, explains.”
Gilead Oncology on Twitter: "For #AMLWorldAwarenessDay, …
WEBFor #AMLWorldAwarenessDay, we’re proud to partner with @BeTheMatch to help connect potential blood stem cell donors to people in need of a transplant. #KnowAML . 21 Apr 2023 17:01:02
Twitter. It’s what’s happening / Twitter
WEBWe would like to show you a description here but the site won’t allow us.
Gilead Oncology on Twitter
WEBJun 2, 2022 · “We’re at #ASCO22 this week to present our latest research and advancements in supporting new innovations in #cancer care. Our ambition is to help bring more life to people with overlooked, underserved and difficult-to-treat cancers.”
Gilead Oncology on Twitter: "At Gilead, we’ve assembled a team …
WEBAt Gilead, we’ve assembled a team with deep and diverse oncology experience. And we’re still growing across all disciplines, from research and clinical operations to regulatory and commercial. Join us: http://gilead.inc/3pCSeym
Blood Cancer UK: Hopes for our community’s future in
WEBSep 30, 2021 · This Blood Cancer Awareness Month, Blood Cancer UK’s Kate Keightley explains the need for better awareness and understanding of this common, but less-understood disease.
Gilead and Kite Oncology Demonstrate Transformative Impact of …
WEBNov 3, 2022 · Gilead and Kite Oncology Demonstrate Transformative Impact of Cell Therapy and Promise of Blood Cancer Portfolio at ASH 2022. -- New Long-Term Data Reinforce Durability of CAR T-Cell Therapy in Lymphoma and Leukemia --. -- New Real-World Evidence Shows Impact of CAR T-Cell Therapy on Patient Outcomes --. -- Updated Data From Magrolimab Studies ...
Gilead Oncology on Twitter: "Triple-negative breast cancer …
WEBTriple-negative breast cancer research and disease awareness has increased in the last 10 years. We’re committed to continue providing more options for those diagnosed. #TNBC
Gilead and Kite Oncology Demonstrate Broad Leadership in Cell …
WEBNov 4, 2021 · “We see broad potential across our oncology portfolio as we advance transformative science for people with hard-to-treat blood cancers.” Researchers will also share early-stage research on magrolimab, an investigational CD47 inhibitor, both in an oral session and in an ASH-EHA Joint Symposium.
Blood Cancer Aware
WEBBlood Cancer Awareness Month was established to increase public understanding of blood cancers and to raise awareness about the need for improved treatments, early diagnosis, and increased funding for research. Find Out More.